1 Alprazolam, a triazolobenzodiazepine, is extensively prescribed for the treatment of anxiety disorders, which predominantly affect women of child-bearing age. The purpose of the present study was to assess the pharmacokinetics of alprazolam and its two hydroxylated metabolites: 4-hydroxy-alprazolam and a-hydroxy-alprazolam in lactating human volunteers and to test the predictability of four recently reported models for drug transfer into milk based on physicochemical properties. 2 Multiple milk and serum samples in eight lactating subjects were collected up to 36 h following single oral doses of 0.5 mg alprazolam; suckling of the infant was discontinued after drug administration. 4-Hydroxy-alprazolam was the predominant metabolite in serum samples while a-hydroxy-alprazolam was not detected. 
Introduction
Benzodiazepines as a class, are the most commonly ized anxiety disorder and panic disorder which are prescribed anxiolytics in the United States. Alprazo-twice as frequently manifested among women than lam (Xanaxe) a triazolo-benzodiazepine introduced in among men [3, 4] . The age of onset is usually 1980, has replaced diazepam as the most widely pre-years old which coincides with age of child bearing. scribed benzodiazepine; partly due to its shorter half-
The incidence of psychiatric illness is higher in the life resulting in less cumulative drowsiness [1, 2] . It first 12 weeks of postpartum than at any other time in is commonly prescribed for the treatment of general-a women's life [5] . Breast feeding has its inherent Correspondence: Dr P. J. McNamara, Division of Pharmacology and Experimental Therapeutics, University of Kentucky, Lexington, Ky 40536 advantages in terms of milk composition, immunoprotection, and bonding [6] . Benzodiazepines such as diazepam, oxazepam, lorazepam, lormetazepam, quazepam, midazolam, nitrazepam, flunitrazepam, metaclazepam and lormetazepam have been found in breast milk to varying degrees, with milk:serum (M/S) ratios ranging from 0.1-3 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . These reports show that neonatal levels were generally low and not associated with obvious adverse effects, with the exception of sedation [16] . However, the impaired ability of the neonate to oxidize and conjugate benzodiazepines prior to their renal elimination continues to be a clinical concern [17] . Faced with limited treatment option, clinicians have a propensity to advise lactating mothers suffering from anxiety or panic disorders to refrain from breast feeding.
Very little is known about the blood-milk transfer of alprazolam, or its two major metabolites: ahydroxy-alprazolam and 4-hydroxy-alprazolam. In a cohort study, mild drowsiness in an infant which resolved spontaneously despite continued therapy was reported in one of the five cases in which alprazolam was being consumed by the breast feeding mothers [18] . However, an estimate of the infant's dose could not be made as no plasma or milk concentrations were assayed. A more rigorous study design is needed to address the potential exposure of alprazolam in view of its prevalent use in women of child bearing age.
Previously, we have proposed a diffusion model to predict the transfer of drug into milk based on physicochemical properties of the drug [19] [20] [21] . The model incorporates pH partition theory, binding to serum and milk proteins, and partitioning into milk fat to make prediction of M/S ratio. A direct comparison of the model predictions with in vivo measurements for a number of model compounds were made using lactating New Zealand White rabbits [20, 21] . Three other diffusional models have been proposed by Atkinson & Begg [22] , Begg & Atkinson [23] , and by Stebler & Guentert [24] . To date, none of these models has been prospectively tested in humans. The availability of a good model is appealing because of its potential to make useful clinical prediction from the physicochemical data.
The purpose of the study was to study the bloodmilk transfer of alprazolam in lactating women and to validate model prediction of M/S ratio from the in vitro determinations.
receive any known enzyme inducing or inhibiting agents for a period of 30 days, or any other medication for a period of 7 days, or alcohol 2 days preceding their participation in this study. An electronic breast pump (Egnell LACT-E, Cary IL) was used for the collection of milk samples. Each subject received a single oral dose of alprazolam (two 0.25 mg Xanax® Tablets). Multiple blood (7 ml) and milk (15- aliquots of buffer and skim milk, which were then counted in a scintillation counter. Volume shift in each chamber, as well as pH of the buffer were measured. The ratio of the buffer to milk is the free fraction in skim milk (fm). Similarly, the free fraction in serum (fs) was determined with serum dialyzed against pH 7.2 phosphate buffer; which increased to approximately 7.4 after 6 h dialysis. Fresh, well mixed milk sample was drawn into a sealed haematocrit tube and centrifuged for 10 min. The length of the creamy layer was measured with a magnifying glass with imprinted micro-scale. The percentage of the length of the creamy layer to the whole length was defined as the crematocrit.
Analytical assay

Methods
Subjects and study design
The study population consisted of eight healthy, nonobese, lactating human volunteers 6-28 weeks postpartum who had decided to stop nursing or suspend nursing for the duration of the study. All subjects signed the informed consent forms according to the University Institutional Review Board prior to their participation in the study. The subjects did not To 2 ml of whole milk, 50 p1 of standard solution (15.6 to 250 ng ml-' of alprazolam, 4-hydroxy-alprazolam and a-hydroxy-alprazolam) and 25 p1 of internal standard (206 ng ml-' diazepam) was added.
Acetonitrile (5 ml) was added dropwise while vortexing gently to precipitate the milk proteins. After standing for 5 min in a -20°C freezer, the supernatants were transferred and evaporated under nitrogen gas until about 0.5 ml remained. Water (1 ml) was added to the remaining supernatant and then loaded into a Bond Elut CN solid-phase extraction cartridge (Varian®, Harbour City, CA), which had been preactivated with 2 ml methanol followed by 2 ml Milli-Q water. The cartridge was rinsed with 1 ml Milli-Q water and centrifuged for 1 Four recently published models have been proposed to predict the distribution of drugs between milk and plasma. Predicted M/S value (M/Spred) can be calculated from the in vitro physicochemical properties of the drug, assuming a passive simple diffusion.
Predicted M/S values of Model 1 (Fleishaker et al., 1987) [19] were derived by assuming only the free, unionized xenobiotic will be able to cross the bloodmilk barrier: Equation 6 and Cr is the crematocrit; Pm is the milk lipid: The regression coefficients (r2) of the four models were used in testing significant difference from one another (Z-test) at P < 0.05 [27] . In addition, the model with the lowest absolute mean error (ME), mean square error (MSE) and root mean square error (RMSE) would be deemed superior [28] .
Results
The mean weight of the eight subjects was 62.7 ± 8.0 kg. The mean postpartum period was 11.8 ± 2.3 weeks. The mean pH of milk prior to drug administration was 7.13 ± 0.12. 4-Hydroxy-alprazolam was found in serum, but not milk, at the detection limit of 0.5-1 ng ml-' or less; a-hydroxy-alprazolam was not detected in any of the samples. The serum and milk concentration-time profile of alprazolam for a representative subject following the oral administration of alprazolam is presented in Figure 1 . Alprazolam concentrations in serum and milk peaked and declined in Table 3 . Model 4 has a higher mean error (-0.146) than Model 1, Model 2 and Model 3 which have similar mean error (-0.063, -0.060, -0.066, respectively) ( Table 3) .
Discussion
Lactation did not change the serum pharmacokinetic parameters of alprazolam except the free serum fraction (f = 18%; literature reported fs = 24-31% [2] ).
The reason for a lower free serum fraction for the study is unclear. Low concentrations of 4-hydroxyalprazolam were detected in serum while ca-hydroxyalprazolam was not detected at all following an oral dose of 0.5 mg alprazolam. This finding is consistent with the literature in that less than 10% of the dose is detected as metabolites in serum, with 4-hydroxyalprazolam as the major metabolite [29] [30] [31] [32] .
As with other benzodiazepines [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , alprazolam is rapidly absorbed and distributed into milk, with the time of peak concentration of both serum and milk around 60 min. The parallel blood and milk concentration-time profile suggests that alprazolam can readily diffuse across the blood-milk barrier in a bidirectional fashion. Peak concentration in milk is 60% lower than serum peak concentration, in line with the M/Sobs value of 0.36. The lower peak concentration in milk and the M/SobS value when compared with other benzodiazepines, such as diazepam may be caused by the lower partitioning into milk fat or S/W (ln octanol:water partition coefficient 468 vs 18 for diazepam and alprazolam, respectively) and a lower serum protein binding of alprazolam compared with diazepam.
The linear and dose-independent nature of alprazolam pharmacokinetics over a wide range of doses have been shown [33, 34] . Hence, extrapolation from the present single dose study to the steady-state situation appears justified. Steady state serum concentration of 20-40 ng ml-' of alprazolam is needed for treating anxiety disorders, while concentrations above 40 ng ml-' may be required for optimal suppression of panic attacks [29] . By using the mean oral clearance (1.15 ml min-' kg-') and the mean observed M/S ratio (0.36) obtained from the present study, the approved range of daily doses of alprazolam of 10-140 ,ug kg-l day-' [29] , and an ingested milk volume of 150 ml kg-' day-' [35] the average dose ingested by the neonate can range from 0.5-5 ,ug kg-l day-' or around 3% of the maternal dose (body weight adjusted).
In order to utilize the infant dose as an indication of neonatal risk during alprazolam exposure via lactation, two assumptions are required. First, the assumption that the clearance of alprazolam (on a body weight basis) is comparable in the infant, hence a similar dose would give rise to comparable serum concentrations. Some evidence would suggest that drug metabolic activity is not fully expressed in the newborn, with reports of the impaired ability of the neonate to oxidize and conjugate benzodiazepines [17] . The second assumption is that the resulting serum concentration of alprazolam would evoke the same pharmacodynamic response in the infant. Pharmacokinetic and pharmacodynamic relationships, in general, have not been well-characterized in the newborn. In this regard, no pharmacokinetic/pharmacodynamic studies of alprazolam have been conducted in the human newborn. Despite these caveats, the present analysis would suggest that alprazolam breast milk concentrations would be low and unlikely to result in any pharmacological effect on the nursing infant. However, good clinical judgement should be exercised in weighing the benefits of breastfeeding versus any potential risk to the infant.
In terms of the predictive models, Model 1, 2 and 3 estimated well the observed M/S; while Model 4 seemed to be inadequate. It should be noted that both Model 1 and 2 use the same three physicochemical characteristics (ionization fraction; protein binding and lipid solubility). The difference being that Model 2 utilized octanol:water partitioning ratio to predict milk fat partitioning while Model 1 incorporated a direct measurement of skim:whole milk concentration ratio. These two models can be regarded as essentially equivalent as they can be derived from each other. Model 3 is derived from regression analysis of Model 2 for a series of weak bases [23] . It should be noted that Model 2 and 3 were derived from a series of drugs and were not intended to be predictive of variation for one drug within a group of subjects [22, 23] .
Comparisons of predictive models should be approached with a specific goal. The original objective of Model 1 was to test the hypothesis that most drugs distribute into milk by passive processes. When substantial deviations from model predictions are observed (i.e., cimetidine in rats [36] ), a mechanism other than passive diffusion, such as active transport, is proposed. To explore mechanisms of drug transfer into milk, Model 1 appears most appropriate given sufficient in vitro data. Model 3 would appear to offer advantages as an a priori prediction based on established physiochemical characteristics of the drug and limited experimental data. Model 4 was used to predict M/S ratio for diazepam when Model 1 and 2 appeared to systematically underpredict the in vivo value in rabbits [24] . The derivation of the Model 4 relationship was not presented [24] and its value to aid in the prediction of mechanism of transfer (passive vs active) or its widespread application to other drugs has not been evaluated.
In conclusion, the neonatal dose of ingested alprazolam is low when alprazolam is administered to the breast-feeding mother. Human M/S ratio for alprazolam was readily predicted from in vitro determinations and the overall results support using diffusional models for predicting transfer of alprazolam into breast milk.
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